FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Andrew Evens, DO, MBA, MSc, discusses the HOLISTIC consortium, which aims to gather and harmonize global Hodgkin lymphoma ...

The FDA designates the TOBY Test as a breakthrough device, revolutionizing bladder cancer detection with a non-invasive, ...

Panelists discuss the rapidly evolving endocrine treatment landscape in oncology, emphasizing the shift toward personalized ...

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic ...

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer ...

Panelists discuss the SERENA-6 trial evaluating camizestrant, which uniquely enrolled patients with molecularly detected ESR1 ...

Panelists discuss recent phase 3 trials introducing novel endocrine agents such as proteolysis-targeting chimeras (PROTACs) ...

Panelists discuss recent phase 3 trials of novel endocrine agents in advanced breast cancer, highlighting benefits—especially ...

Panelists discuss the EMBER-3 trial, which evaluated single-agent oral selective estrogen receptor degrader (SERD) ...